Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia
Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia
NCT ID: NCT06948864 Phase: Status: COMPLETED Enrollment: 152 Completion: 2024-12-31
Conditions
Anemia, Anemia (Iron-Loading), Perioperative Bleeding, Infection Prevention, Readmission, Hospital, Surgical Complication, Length of Hospital Stay, Iron Deficiency Anemia Treatment, Prehabilitation
Interventions
Ferric Carboxymaltose (FCM)
Summary
The prevalence of preoperative anaemia in patients undergoing major surgery is approximately 30%, and is independently associated with higher mortality, a higher rate of postoperative complications, and a greater probability of receiving a transfusion. In a prehabilitation program, the evaluation and correction of anaemia in the preoperative period is essential, as it is a risk factor for transfusions and complications. The main objectives of this study were to analyse the need for blood transfusion, post-surgical complications, hospital length of stay, ICU length of stay, hospital readmissions, and surgical wound infection in patients treated with ferric carboxymaltose (FC) before surgery. A total of 152 patients were included, of whom 96 received FC before the intervention and 56 received no treatment (control group).
Primary Outcome
Analyze levels of Hemoglobine